EGFR and non-small cell lung carcinoma: Recently, osimertinib has been shown to exert remarkable effects against untreated EGFR mutation-positive advanced NSCLC as well as those with EGFR-TKI-sensitizing and EGFR T790 M resistance mutations [4].